A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

作者: Y.G. Najjar , K. Mittal , P. Elson , L. Wood , J.A. Garcia

DOI: 10.1016/J.EJCA.2014.01.025

关键词:

摘要: … Empirically, several mRCC patients at The Cleveland Clinic (CCF) have been changed from schedule 4/2 to 2 weeks of treatment/1 week off (schedule 2/1) after experiencing toxicity, in …

参考文章(8)
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini, Jean-Pierre Armand, Paul Scigalla, Eric Raymond, Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Journal of Clinical Oncology. ,vol. 24, pp. 25- 35 ,(2006) , 10.1200/JCO.2005.02.2194
Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen, George D. Demetri, Robert J. Motzer, Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemotherapy and Pharmacology. ,vol. 66, pp. 357- 371 ,(2010) , 10.1007/S00280-009-1170-Y
Yana G. Najjar, Brian I. Rini, Novel agents in renal carcinoma: a reality check: Therapeutic Advances in Medical Oncology. ,vol. 4, pp. 183- 194 ,(2012) , 10.1177/1758834012443725
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul W. Bycott, Charles M. Baum, Robert A. Figlin, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 115- 124 ,(2007) , 10.1056/NEJMOA065044
Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen, Gary R. Hudes, John M. Burke, William J. Edenfield, George Wilding, Neeraj Agarwal, John A. Thompson, David Cella, Akintunde Bello, Beata Korytowsky, Jinyu Yuan, Olga Valota, Bridget Martell, Subramanian Hariharan, Robert A. Figlin, Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 30, pp. 1371- 1377 ,(2012) , 10.1200/JCO.2011.36.4133
Georg A. Bjarnason, Naveen S. Basappa, Jennifer J. Knox, Christian K. Kollmannsberger, M. Neil Neil Reaume, Pawel Zalewski, Robyn Jane Macfarlane, Mary J. MacKenzie, Sebastien J. Hotte, Daniel Yick Chin Heng, Denis Soulieres, Jessie Miller, A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.TPS4594
Bradley J. Atkinson, Sarathi Kalra, Xuemei Wang, Tharakeswara Bathala, John Perpich, Paul Gettys Corn, Nizar M. Tannir, Eric Jonasch, Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. Journal of Clinical Oncology. ,vol. 31, pp. e15611- e15611 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.E15611
Bradley J. Atkinson, Sarathi Kalra, Xuemei Wang, Nizar M. Tannir, Eric Jonasch, A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. Journal of Clinical Oncology. ,vol. 31, pp. 381- 381 ,(2013) , 10.1200/JCO.2013.31.6_SUPPL.381